Technical Analysis for NBIX - Neurocrine Biosciences, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 132.54 | -0.52% | -0.69 |
Earnings due: May 1
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Lower Bollinger Band Walk | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Stochastic Buy Signal | Bullish | -0.52% | |
NR7 | Range Contraction | -0.52% | |
Doji - Bullish? | Reversal | -0.52% | |
Lower Bollinger Band Walk | Weakness | -0.52% | |
Lower Bollinger Band Touch | Weakness | -0.52% | |
Oversold Stochastic | Weakness | -0.52% | |
Pocket Pivot | Bullish Swing Setup | -0.34% |
Alert | Time |
---|---|
Possible NR7 | about 17 hours ago |
Possible Inside Day | about 17 hours ago |
Gap Down Partially Closed | about 21 hours ago |
Gap Down Closed | about 21 hours ago |
Reversed from Down | about 21 hours ago |
Get a Trading Assistant
- Earnings date: 05/01/2024
Neurocrine Biosciences, Inc. Description
Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF2 Peptide Agonist, a Phase II drug for cardiovascular diseases; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for schizophrenia; gonadotropin-releasing hormone (GnRH) Antagonists for men's and women's health, and oncology; Antiepileptic Drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled Receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Clinical Development Diabetes Alcohol Disorders Cardiovascular Disease Schizophrenia Vascular Disease Epilepsy Hormones Ethers Movement Disorders Insomnia Transporter Type I Diabetes Endometriosis Essential Tremor Fibroids Type II Diabetes Uterine Fibroid Dyskinesia Gnrh Antagonists Neurocrine Biosciences
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 148.3699 |
52 Week Low | 89.04 |
Average Volume | 906,409 |
200-Day Moving Average | 120.16 |
50-Day Moving Average | 136.17 |
20-Day Moving Average | 137.66 |
10-Day Moving Average | 135.65 |
Average True Range | 3.82 |
RSI (14) | 39.02 |
ADX | 16.56 |
+DI | 10.95 |
-DI | 19.58 |
Chandelier Exit (Long, 3 ATRs) | 136.92 |
Chandelier Exit (Short, 3 ATRs) | 142.45 |
Upper Bollinger Bands | 144.07 |
Lower Bollinger Band | 131.25 |
Percent B (%b) | 0.1 |
BandWidth | 9.31 |
MACD Line | -1.21 |
MACD Signal Line | -0.36 |
MACD Histogram | -0.8546 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 137.34 | ||||
Resistance 3 (R3) | 137.36 | 135.78 | 136.54 | ||
Resistance 2 (R2) | 135.78 | 134.56 | 135.77 | 136.27 | |
Resistance 1 (R1) | 134.16 | 133.80 | 133.37 | 134.14 | 136.01 |
Pivot Point | 132.58 | 132.58 | 132.19 | 132.57 | 132.58 |
Support 1 (S1) | 130.96 | 131.36 | 130.17 | 130.94 | 129.07 |
Support 2 (S2) | 129.38 | 130.60 | 129.37 | 128.81 | |
Support 3 (S3) | 127.76 | 129.38 | 128.54 | ||
Support 4 (S4) | 127.74 |